Anticancer

(S)-10-Hydroxycamptothecin
Catalog No: CFN99735

(S)-10-Hydroxycamptothecin is a DNA topoisomerase I inhibitor, it is a clinical therapy agent against hepatoma.

10-Hydroxycamptothecin
Catalog No: CFN99736

10-Hydroxycamptothecin is a cell-permeable powerful DNA topoisomerase I inhibitor. It has selective inhibitory effect on the phosphorylation of histone H1 and H3, but less effect on other histones.10-Hydroxycamptothecin anticancer, and antiangiogenic activities, it can prevent fibroblast proliferation and epidural scar adhesion after laminectomy in rats.

Myrislignan
Catalog No: CFN99752

Myrislignan has anti-inflammatory, and anti-cancer activities, it inhibited NF-κB signalling pathway activation, inhibited the proliferation of A549 cells in a dose- and time-dependent manner, it also significantly induced apoptosis and cell cycle arrest in A549 cells.

Alisol B 23-acetate
Catalog No: CFN99753

Alisol B 23-acetate, a partial non-competitive inhibitor of P-gp, it may be a potential MDR reversal agent. Alisol B 23-acetate produces protective effects against ANIT-induced hepatotoxity and cholestasis, due to FXR-mediated gene regulation; it obviously inhibits proliferation of the three ovarian cancer cell lines, possesses anti-proliferation, anti-migration and anti-invasion activities as a single agent on ovarian cancer cells.

Ginsenoside F1
Catalog No: CFN99754

Ginsenoside has been reported to suppress platelet aggregation and to reduce gap junction-mediated intercellular communication, also as a novel anti-skin cancer drug with anti-proliferative and anti-migration features. Ginsenoside F1 has a potential for industrial cosmetic materials, it also has inhibitory effect of elastase and tyrosinase, it significantly reduces ultraviolet-B-induced cell death by maintaining constant levels of Bcl-2 and protects HaCaT cells from apoptosis caused by ultraviolet B irradiation.